Market research
B4V.F ArcticZymes Technologies ASA
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 96M
- P/E ratio
- 62.33
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.56
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- NO0010014632
- Market cap
- 96M
- P/E ratio
- 62.33
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.56
About
About ArcticZymes Technologies ASA
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools market, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the B4V.F discussion.
5 years, 5 months ago
ArcticZymes Technologies ASA is currently in a long term uptrend where the price is trading 28.8% above its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 27.6.
ArcticZymes Technologies ASA's total revenue rose by 71.2% to $32M since the same quarter in the previous year.
Its net income has increased by 721.4% to $9M since the same quarter in the previous year.
Finally, its free cash flow grew by 23.1% to $12M since the same quarter in the previous year.
Based on the above factors, ArcticZymes Technologies ASA gets an overall score of 5/5.